JP2015521041A5 - - Google Patents

Download PDF

Info

Publication number
JP2015521041A5
JP2015521041A5 JP2015511948A JP2015511948A JP2015521041A5 JP 2015521041 A5 JP2015521041 A5 JP 2015521041A5 JP 2015511948 A JP2015511948 A JP 2015511948A JP 2015511948 A JP2015511948 A JP 2015511948A JP 2015521041 A5 JP2015521041 A5 JP 2015521041A5
Authority
JP
Japan
Prior art keywords
pkn3
inhibitor
vegfr1
suffering
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015511948A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015521041A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/001441 external-priority patent/WO2013170960A1/en
Publication of JP2015521041A publication Critical patent/JP2015521041A/ja
Publication of JP2015521041A5 publication Critical patent/JP2015521041A5/ja
Pending legal-status Critical Current

Links

JP2015511948A 2012-05-16 2013-05-15 Pkn3阻害剤投与のためのバイオマーカーとしてのvegfr1の使用 Pending JP2015521041A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12003888 2012-05-16
EP12003888.0 2012-05-16
PCT/EP2013/001441 WO2013170960A1 (en) 2012-05-16 2013-05-15 Use of vegfr1 as a biomarker for pkn3 inhibitor administration

Publications (2)

Publication Number Publication Date
JP2015521041A JP2015521041A (ja) 2015-07-27
JP2015521041A5 true JP2015521041A5 (enExample) 2016-07-07

Family

ID=48446240

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015511948A Pending JP2015521041A (ja) 2012-05-16 2013-05-15 Pkn3阻害剤投与のためのバイオマーカーとしてのvegfr1の使用

Country Status (4)

Country Link
US (2) US9133515B2 (enExample)
EP (1) EP2849771A1 (enExample)
JP (1) JP2015521041A (enExample)
WO (1) WO2013170960A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016083623A1 (en) * 2014-11-28 2016-06-02 Silence Therapeutics Gmbh Means for the treatment of pre-eclampsia
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR970002255B1 (ko) 1990-06-11 1997-02-26 넥스스타 파아마슈티컬드, 인크. 핵산 리간드
US20040220128A1 (en) * 1995-10-26 2004-11-04 Sirna Therapeutics, Inc. Nucleic acid based modulation of female reproductive diseases and conditions
AU743469C (en) 1996-08-30 2004-02-12 Rolf Bald Mirror-symmetrical selection and evolution of nucleic acids
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
US5989912A (en) 1996-11-21 1999-11-23 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
ATE450621T2 (de) 2000-03-30 2009-12-15 Whitehead Biomedical Inst Mediatoren von rns-interferenz, die rns- sequenzspezifisch sind
WO2004019973A1 (en) 2002-08-14 2004-03-11 Atugen Ag Use of protein kinase n beta
RU2553561C2 (ru) 2006-07-21 2015-06-20 Сайленс Терапьютикс Аг Средства ингибирования экспрессии протеинкиназы 3

Similar Documents

Publication Publication Date Title
CY1122796T1 (el) Βελτιωμενες φαρμακοτεχνικες μορφες αδενοϊων
LT3321276T (lt) Sulieti baltymai, skirti metabolinių sutrikimų gydymui
JP2015503422A5 (enExample)
LT2945642T (lt) Faktoriaus 1 baltymas, skirtas naudoti ligų gydymui arba prevencijai
JP2015513557A5 (enExample)
LT3206716T (lt) Kanabinoidų panaudojimas atoninių traukulių gydymui, esant lennox-gastaut' sindromui
HK1223795A1 (zh) 拉喹莫德响应性的基因表达生物标志物
IL231228A0 (en) Bicyclic heterocycle derivatives for the treatmen t of pulmonary arterial hypertension
HUE049323T2 (hu) Hízósejt-stabilizálók tüdõbetegség kezelésére
IL231591A0 (en) Converted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases
JP2015520667A5 (enExample)
LT2780370T (lt) Anti-adrenomedulino (adm) antikūnas arba anti-adm antikūno fragmentas, arba anti-adm ne ig karkasas, skirtas panaudoti paciento ūmios ligos arba ūmios būklės terapijoje kraujotakai stabilizuoti
HUE045724T2 (hu) GRPR antagonisták GRPR-pozitív rák kimutatására, diagnózisára és kezelésére
WO2012112315A3 (en) Methods for diagnosis of kawasaki disease
EA201590359A1 (ru) Лечение ревматоидного артрита
CY2020015I2 (el) Σικλεσονιδη για τη θεραπεια της νοσου των αεραγωγων σε αλογα
HK1212713A1 (zh) Vegfr1抗體的治療性用途
HRP20260138T1 (hr) Postupak priprave 2,3,3,3-tetrafluoropropena
IL264382B (en) Compounds for treating the remyelination blockade in diseases associated with the expression of herv-w envelope protein
HUE053229T2 (hu) FK506 alkalmazása pulmonális artériás hipertenzió kezelésére
EP2956475A4 (en) MODIFIED INGAP PEPTIDES FOR THE TREATMENT OF DIABETES
IL262664B (en) Compositions for treating or preventing vasomotor symptoms
BR112017021413A2 (pt) anticorpos anti-flt-1 no tratamento da displasia broncopulmonar.
LT2872145T (lt) Sujungti benzazepinai tureto sindromui gydyti
EA201692013A1 (ru) Новое применение n,n-бис-2-меркаптоэтил-изофталамида